Clarus Therapeutics Touts Phase 3 Success for Oral Testosterone Replacement Therapy
9/25/2012 7:29:45 AM
More...
|
Clarus Therapeutics Strengthens Patent Estate With Issuance of a U.S. Patent Directed to Formulations and Method of Use of Clarus' Oral Testosterone Product
9/19/2012 9:26:21 AM
More...
|
Clarus Therapeutics Appoints Bela S. Denes, M.D. as Chief Medical Officer
6/21/2012 7:40:26 AM
More...
|
Clarus Therapeutics Completes Patient Enrollment in Phase 3 Study of its Proprietary Oral Testosterone Replacement Therapy
5/1/2012 10:13:25 AM
More...
|
Biotech Clarus Therapeutics Files for $86 Million IPO
11/23/2010 7:28:22 AM
More...
|
Clarus Therapeutics Announces Completion of $8 Million Series C Financing Round
11/27/2007 10:48:23 AM
More...
|